These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3564834)

  • 1. Discrimination of type I from insulin-treated type II diabetic patients by C-peptide measurement.
    Cravarezza P; Radaeli E; Toffoli C; Rigosa C
    Acta Diabetol Lat; 1986; 23(4):345-50. PubMed ID: 3564834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics in the discrimination between patients with low or high C-peptide level among middle-aged insulin-treated diabetics.
    Laakso M; Sarlund H; Pyörälä K
    Diabetes Res; 1987 Feb; 4(2):95-9. PubMed ID: 3581663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.
    Gjessing HJ; Matzen LE; Faber OK; Frøland A
    Diabetologia; 1989 May; 32(5):305-11. PubMed ID: 2666217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasting, postprandial and postprandial plus glucagon-stimulated plasma C-peptide levels in non-insulin-dependent diabetics and in control subjects.
    Sarlund H; Laakso M; Pyörälä K; Penttilä I
    Acta Med Scand; 1987; 221(4):377-83. PubMed ID: 3604753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [C-peptide as the decisive factor for classification of type 1 diabetes mellitus and type 2 diabetes mellitus].
    Perusicová J; Bárová H; Hill M; Masek Z
    Vnitr Lek; 2002 Jun; 48(6):490-9. PubMed ID: 12132349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma glucose response after intravenous injection of tolbutamide in insulin-treated type I and type II diabetic patients.
    Mokuda O; Murakami I; Ikeda T; Tominaga M; Mashiba H
    Exp Clin Endocrinol; 1988 Aug; 91(3):265-70. PubMed ID: 3075183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of measuring serum c-peptide before and after glucagon injection].
    Kan Y; Chi Z
    Zhonghua Yi Xue Za Zhi; 1991 Jan; 71(1):16-7, 4. PubMed ID: 1850647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and urinary C-peptide in the classification of adult diabetics.
    Koskinen P; Viikari J; Irjala K; Kaihola HL; Seppälä P
    Scand J Clin Lab Invest; 1986 Nov; 46(7):655-63. PubMed ID: 3538365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [C-peptide assays of the urine and plasma at baseline and under stimulation with glucagon in healthy subjects and diabetics].
    Sabot O; Tourniaire J; Charrie A; Rebattu B; Jouve M; Ayzac L; Fleury MC
    Presse Med; 1990 May; 19(18):860-3. PubMed ID: 2140181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-peptide determination in the choice of treatment in diabetes mellitus.
    Koskinen P; Viikari J; Irjala K; Kaihola HL; Seppälä P
    Scand J Clin Lab Invest; 1985 Nov; 45(7):589-97. PubMed ID: 3906851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum C-peptide concentrations and their value in evaluating the usefulness of insulin therapy in elderly diabetics.
    Kyllästinen M; Elfving S
    Gerontology; 1986; 32(6):317-26. PubMed ID: 3556328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of beta-cell function in diabetic Taiwanese children using a 6-min glucagon test.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    Eur J Pediatr; 2008 Jul; 167(7):801-5. PubMed ID: 17874132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
    Iwasaki Y; Kondo K; Hasegawa H; Oiso Y
    Diabetes Res; 1994; 25(3):129-37. PubMed ID: 7671552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [beta-Cell residual function in juvenile diabetes mellitus (author's transl)].
    Schober E; Schernthaner G; Frisch H
    Monatsschr Kinderheilkd; 1980 Dec; 128(12):776-9. PubMed ID: 6109242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum ketone response to glucagon as a marker of insulin dependency in diabetics.
    Watanabe T; Sugiyama H; Uchimura I; Maezawa H
    Diabetes Res Clin Pract; 1991 Nov; 14(2):107-12. PubMed ID: 1756681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma C-peptide and insulin responses to intravenous glucagon stimulation in idiopathic haemochromatosis.
    Rumbak MJ; Joffe BI; Seftel HC; Kalk WJ; Bezwoda WR; Bothwell TH
    S Afr Med J; 1987 Mar; 71(6):351-3. PubMed ID: 3551126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproducibility of the glucagon test.
    Arnold-Larsen S; Madsbad S; Kühl C
    Diabet Med; 1987; 4(4):299-303. PubMed ID: 2956039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics.
    Gjessing HJ; Matzen LE; Frøland A; Faber OK
    Diabetes Care; 1987; 10(4):487-90. PubMed ID: 3304899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-stimulated and postprandial plasma C-peptide values as measures of insulin secretory capacity.
    Koskinen PJ; Viikari JS; Irjala KM
    Diabetes Care; 1988 Apr; 11(4):318-22. PubMed ID: 3042307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.